Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients

被引:14
|
作者
Pease, Daniel F. [1 ]
Ross, Julie A. [2 ]
Poynter, Jenny N. [2 ]
Nguyen, Phuong L. [3 ]
Hirsch, Betsy [4 ]
Cioc, Adina [5 ]
Roesler, Michelle A. [2 ,6 ]
Warlick, Erica D. [7 ]
机构
[1] Hennepin Cty Med Ctr, Dept Med, Minneapolis, MN 55415 USA
[2] Univ Minnesota, Dept Pediat, Minneapolis, MN 55454 USA
[3] Mayo Clin, Div Hematopathol, Rochester, MN 55905 USA
[4] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[5] VA Med Ctr, Hematopathol, Minneapolis, MN 55417 USA
[6] Univ Minnesota, Mason Canc Ctr, Minneapolis, MN 55455 USA
[7] Univ Minnesota, Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA
关键词
Myelodysplastic syndromes; Hematologic malignancies; Drug therapy; Bone marrow transplantation; STEM-CELL TRANSPLANTATION; PROGNOSTIC SCORING SYSTEM; RETROSPECTIVE MULTICENTER ANALYSIS; CONVENTIONAL CARE REGIMENS; IDENTICAL SIBLING DONORS; ACUTE MYELOID-LEUKEMIA; DECISION-ANALYSIS; OLDER PATIENTS; PHASE-III; THERAPY;
D O I
10.1016/j.canep.2015.01.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: The heterogeneous nature of myelodysplastic syndromes (MDS) complicates therapeutic decision making, particularly for newly diagnosed disease. Factors impacting the treatment plan in this early period of disease course are poorly defined. This study determines whether therapeutic choices for newly diagnosed MDS are associated with location of treatment (community or academic), prognostic risk category, and patient age. Methods: The adults in Minnesota with myelodysplastic syndromes (AIMMS) database was utilized in this statewide, prospective population-based study conducted by the University of Minnesota (UMN), Mayo Clinic, and Minnesota Department of Health. Adult (age 20+ years) cases of MDS newly diagnosed starting in April 2010 were invited to participate. This analysis includes patients enrolled during the first study year with 1-year follow-up data. Treatment choices (supportive, active, and transplant) were stratified by the international prognostic scoring system (IPSS) and the revised-IPSS (IPSS-R), then separated into groups by location of care and age (<65 or 65+ years). Academic-based care was any contact with the UMN and Mayo Clinic; community-based care was all other clinical sites. Results: Stratification by IPSS and IPSS-R showed supportive care decreased and active care increased with advancing risk categories (p < 0.0001). Comparing treatment setting, community-based care had 77% supportive and 23% active treatment; academic-based care was 36% supportive, 41% active, and 23% transplant (p < 0.0001). By age groups, patients < 65 years with intermediate, high, or very high risk disease by IPSS-R received 97% active care/transplant, compared to only 52% of patients age 65+. Conclusions: Younger patients and those treated at academic centers had a more aggressive treatment approach. Whether these treatment differences convey improved disease control and mortality, and therefore should be extended more frequently to older and community-based patients, is the subject of ongoing prospective study. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:222 / 228
页数:7
相关论文
共 50 条
  • [1] Differences In Community and Academic Practice Patterns For Newly Diagnosed Myelodysplastic Syndromes (MDS) Patients In Minnesota: A Population Based Study
    Pease, Daniel
    Ross, Julie A.
    Nguyen, Phuong L.
    Hirsch, Betsy
    Cioc, Adina
    Smith, Angela R.
    Roesler, Michelle A.
    Fonstad, Rachel K.
    Warlick, Erica D.
    BLOOD, 2013, 122 (21)
  • [2] Real-World Treatment Patterns and Transfusion Burden Among US Patients with Newly Diagnosed Myelodysplastic Syndromes (MDS)
    Mukherjee, Sudipto
    Slabaugh, S. Lane
    Copher, Ronda
    Johnson, Jonathan
    Buzinec, Paul
    Mearns, Elizabeth S.
    BLOOD, 2019, 134
  • [3] SYMPTOM BURDEN OF PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) RECEIVING OUTPATIENT CANCER CARE
    Desai, A. V.
    Goldberg, J. I.
    Anderson, K.
    Ranaghan, C.
    O'shea, D.
    Chow, K.
    Kramer, D.
    Rawlins, R.
    Wan, P. J.
    Klimek, V. M.
    Nelson, J. E.
    LEUKEMIA RESEARCH, 2017, 55 : S128 - S128
  • [4] CLINICIAN UTILIZATION OF THE INTERNATIONAL PROGNOSTIC SCORING SYSTEM (IPSS) FOR NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) PATIENTS
    Pease, D.
    Ross, J.
    Poynter, J.
    Nguyen, P.
    Hirsch, B.
    Cioc, A.
    Roesler, M.
    Warlick, E.
    LEUKEMIA RESEARCH, 2015, 39 : S118 - S118
  • [5] CHROMOTHRIPSIS IN BONE MARROW CELLS OF ADULT PATIENTS WITH NEWLY DIAGNOSED MYELODYSPLASTIC SYNDROMES (MDS) WITH COMPLEX KARYOTYPES.
    Zemanova, Z.
    Lhotska, H.
    Brezinova, J.
    Lizcova, L.
    Svobodova, K.
    Sarova, I.
    Izakova, S.
    Ransdorfova, S.
    Krejcik, Z.
    Dostalova, M.
    Siskova, M.
    Jonasova, A.
    Neuwirtova, R.
    Cermak, J.
    Michalova, K.
    HAEMATOLOGICA, 2014, 99 : 82 - 82
  • [6] Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Registry
    George, Tracy I.
    Cogle, Christopher R.
    Garcia-Manero, Guillermo
    Grinblatt, David L.
    Komrokji, Rami
    Savona, Michael R.
    Scott, Bart L.
    Sekeres, Mikkael A.
    Steensma, David P.
    Flick, E. Dawn
    Kiselev, Pavel
    Louis, Chrystal U.
    Nifenecker, Melissa
    Swern, Arlene S.
    Foucar, Kathryn
    BLOOD, 2019, 134
  • [7] Diagnostic Testing Patterns for Ring Sideroblasts (RS) in Patients with Newly Diagnosed Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Connect® MDS/AML Disease Registry
    Patel, Jay
    Cogle, Christopher
    Foucar, Kathryn
    Grinblatt, David
    Komrokji, Rami
    Savona, Michael
    Scott, Bart
    Sekeres, Mikkael
    Steensma, David
    Flick, Dawn
    Kiselev, Pavel
    Louis, Chrystal
    Nifenecker, Melissa
    Swern, Arlene
    George, Tracy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S343 - S344
  • [8] Flow cytometric patterns in myelodysplastic syndromes (MDS)
    Singleton, TP
    Phadke, DM
    LABORATORY INVESTIGATION, 2002, 82 (01) : 264A - 264A
  • [9] Flow cytometric patterns in myelodysplastic syndromes (MDS)
    Singleton, TP
    Phadke, DM
    MODERN PATHOLOGY, 2002, 15 (01) : 264A - 264A
  • [10] Double induction (DI) chemotherapy for patients (pts) with newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS).
    Garcia-Manero, G
    Faderl, S
    Giles, F
    Verstovsek, S
    Beran, M
    Andreeff, M
    Cortes, J
    Thomas, D
    Koller, C
    Pierce, S
    Ouzonian, S
    Kantarjian, H
    Estey, E
    BLOOD, 2002, 100 (11) : 342A - 342A